Daniel Adelman MD

Currently the Chief Medical Officer at Aimmune Therapeutics, Daniel has an exceptional history leading drug development at biotechnology companies for more than 20 years. Prior to Aimmune, he served as Chief Medical Officer and Senior Vice President of Development at Alvine Pharmaceuticals and Sunesis, and filled various roles at Pharmacyclics, and Genentech. As an allergist and immunologist, he has also taught and practiced medicine at UCSF for more than 25 years and published extensively in allergy, clinical immunology and autoimmunity, and oncology. Dan has served on the research advisory board of Food Allergy Research & Education (FARE) and on the editorial board of the Journal of Allergy and Clinical Immunology, and he now serves on several clinical and scientific advisory boards in addition to the editorial boards of Clinical Immunology and Journal of Clinical Immunology.